Science Advances publishes proteomics technology from Oblique Therapeutics AB with a potential to bring several novel antibody medicines to large patient populations in multiple disease areas
a
Sweden-based biotech company, in collaboration with Karolinska Institutet (Stockholm, Sweden), Gothenburg University (Sweden) and several local biotechs published promising research results in the highly-acclaimed scientific journal
Science Advances The peer-reviewed article describes how Oblique Therapeutics AbiProt
technology can be used to discover and develop pharmacologically tailored antibodies against clinically important targets widely considered undruggable with antibodies. Two example antibodies are presented in the article. One is targeting
h
TRPV1, a clinically validated pain target. The second antibody is targeting KRAS,
Science Advances publishes proteomics technology from Oblique Therapeutics AB with a potential to bring several novel antibody medicines to large patient populations in multiple disease areas
di.se - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from di.se Daily Mail and Mail on Sunday newspapers.
Science Advances publishes proteomics technology from Oblique Therapeutics AB with a potential to bring several novel antibody medicines to large patient populations in multiple disease areas
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
E-Mail
Science Advances publishes proteomics technology from Oblique Therapeutics AB with a potential to bring several novel antibody medicines to large patient populations in multiple disease areas
Gothenburg, Sweden, April 16th, 2021 - Oblique Therapeutics AB, a Sweden-based biotech company, in collaboration with Karolinska Institutet (Stockholm, Sweden), Gothenburg University (Sweden) and several local biotechs published promising research results in the highly-acclaimed scientific journal
Science Advances (AAAS) entitled: Rational Antibody design for Undruggable Targets using Kinetically Controlled Biomolecular probes. The peer-reviewed article describes how Oblique Therapeutics´ Abiprot® technology can be used to discover and develop pharmacologically tailored antibodies against clinically important targets widely considered undruggable with antibodies. Two example antibodies are presented in the article. One is targeting hTRPV1, a clinically validated pain target. The